Barclays Cuts CyberArk (CYBR) To “Hold”; Last Week Eleven Biotherapeutics (EBIO) Analysts

July 17, 2017 - By Darrin Black

Among 2 analysts covering Eleven Biotherapeutics (NASDAQ:EBIO), 0 have Buy rating, 0 Sell and 2 Hold. Therefore 0 are positive. Eleven Biotherapeutics had 4 analyst reports since August 15, 2015 according to SRatingsIntel. Leerink Swann maintained Eleven Biotherapeutics Inc (NASDAQ:EBIO) rating on Saturday, August 15. Leerink Swann has “Outperform” rating and $8.35 target. The firm has “Neutral” rating by Citigroup given on Tuesday, January 19. The company was downgraded on Tuesday, January 19 by Leerink Swann. Citigroup maintained Eleven Biotherapeutics Inc (NASDAQ:EBIO) on Wednesday, March 16 with “Neutral” rating. See Eleven Biotherapeutics Inc (NASDAQ:EBIO) latest ratings:

Among 23 analysts covering Cyber-Ark Software (NASDAQ:CYBR), 15 have Buy rating, 0 Sell and 8 Hold. Therefore 65% are positive. Cyber-Ark Software has $72 highest and $41 lowest target. $57.06’s average target is 33.69% above currents $42.68 stock price. Cyber-Ark Software had 50 analyst reports since July 21, 2015 according to SRatingsIntel. As per Friday, July 14, the company rating was downgraded by Deutsche Bank. Summit Research upgraded Cyberark Software Ltd (NASDAQ:CYBR) rating on Monday, March 14. Summit Research has “Buy” rating and $50 target. The stock of Cyberark Software Ltd (NASDAQ:CYBR) has “Buy” rating given on Thursday, July 13 by Evercore. The rating was upgraded by Goldman Sachs on Thursday, March 30 to “Buy”. As per Tuesday, September 1, the company rating was upgraded by Piper Jaffray. The stock of Cyberark Software Ltd (NASDAQ:CYBR) earned “Hold” rating by J.P. Morgan on Friday, July 14. The firm has “Overweight” rating by Stephens given on Tuesday, April 19. Nomura upgraded the stock to “Buy” rating in Friday, September 25 report. Deutsche Bank maintained it with “Buy” rating and $50 target in Friday, February 12 report. Imperial Capital upgraded the stock to “Outperform” rating in Monday, November 7 report.

It closed at $1.53 lastly. It is down 30.97% since July 17, 2016 and is uptrending. It has outperformed by 14.27% the S&P500.

Investors sentiment decreased to 1 in 2016 Q4. Its down 1.29, from 2.29 in 2016Q3. It worsened, as 6 investors sold Eleven Biotherapeutics Inc shares while 5 reduced holdings. 5 funds opened positions while 6 raised stakes. 1.14 million shares or 22.20% more from 933,766 shares in 2016Q3 were reported. The Texas-based Eagle Global Advisors Ltd Liability has invested 0% in Eleven Biotherapeutics Inc (NASDAQ:EBIO). Price T Rowe Associate Md holds 0% or 28,200 shares. Citigroup Inc holds 500 shares. Reilly Financial Advsr Limited Co holds 0% or 100 shares in its portfolio. Blackrock Fund Advisors, a California-based fund reported 2,365 shares. Northern Corporation owns 17,976 shares or 0% of their US portfolio. Royal Bancshares Of Canada stated it has 0% of its portfolio in Eleven Biotherapeutics Inc (NASDAQ:EBIO). Moreover, Vanguard Group has 0% invested in Eleven Biotherapeutics Inc (NASDAQ:EBIO). 140,500 are owned by Spark Invest Mgmt Ltd Liability Com. Oxford Asset owns 179,627 shares or 0.02% of their US portfolio. Barclays Plc reported 0% stake. Blackrock Institutional Na invested in 442,085 shares. Morgan Stanley reported 4,080 shares. Credit Suisse Ag has invested 0% of its portfolio in Eleven Biotherapeutics Inc (NASDAQ:EBIO). Fiduciary Tru owns 10,000 shares or 0% of their US portfolio.

Eleven Biotherapeutics, Inc. is a preclinical-stage biopharmaceutical company. The company has market cap of $37.79 million. The Firm applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. It has a 7.97 P/E ratio. The Company’s product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema and uveitis.

CyberArk Software Ltd is an Israel-based well-known provider of information technology security solutions that protects organizations from cyber-attacks. The company has market cap of $1.24 billion. The Company’s software solutions are focused on protecting privileged accounts, which have become a critical target in the lifecycle of cyber-attacks. It has a 48.78 P/E ratio. The Company’s Privileged Account Security Solution consists of various products, such as Shares Technology Platform, Enterprise Password Vault, SSH Key Manager, Privileged Session Manager, Privileged Threat Analytics, Application Identity Manager, CyberArk-Conjur, Endpoint Privilege Manager and On-Demand Privileges Manager.